Shenyang Xingqi Pharmaceutical Co.,Ltd.

XSEC:300573 Stock Report

Market Cap: CN¥12.8b

Shenyang Xingqi PharmaceuticalLtd Past Earnings Performance

Past criteria checks 6/6

Shenyang Xingqi PharmaceuticalLtd has been growing earnings at an average annual rate of 32.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 23.9% per year. Shenyang Xingqi PharmaceuticalLtd's return on equity is 21.4%, and it has net margins of 19.3%.

Key information

32.5%

Earnings growth rate

30.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate23.9%
Return on equity21.4%
Net Margin19.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shenyang Xingqi PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300573 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,802348806185
30 Jun 241,674322759168
31 Mar 241,531255715177
31 Dec 231,468240693167
30 Sep 231,350191657177
30 Jun 231,335179666173
31 Mar 231,234157631152
01 Jan 231,250212596146
30 Sep 221,262241586117
30 Jun 221,166235527101
31 Mar 221,12323649491
01 Jan 221,02819545688
30 Sep 2199019044177
30 Jun 2191415341570
31 Mar 2181313236370
31 Dec 206898832263
30 Sep 206026128961
30 Jun 205284526161
31 Mar 205142427857
31 Dec 195423629454
30 Sep 195042928354
30 Jun 194802127746
31 Mar 194531726442
31 Dec 184311424741
30 Sep 184161123836
30 Jun 18379919654
31 Mar 183622817543
31 Dec 173603917734
30 Sep 173615117426
30 Jun 17356512050
31 Mar 17347551980
31 Dec 16339541870
31 Dec 15287221580
31 Dec 14255311530
31 Dec 13219461330

Quality Earnings: 300573 has high quality earnings.

Growing Profit Margin: 300573's current net profit margins (19.3%) are higher than last year (14.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300573's earnings have grown significantly by 32.5% per year over the past 5 years.

Accelerating Growth: 300573's earnings growth over the past year (82.3%) exceeds its 5-year average (32.5% per year).

Earnings vs Industry: 300573 earnings growth over the past year (82.3%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 300573's Return on Equity (21.4%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 02:27
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenyang Xingqi Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tielin ChenTopsperity Securities
Jing ChenTopsperity Securities